D N Rush
Overview
Explore the profile of D N Rush including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiebe C, Gareau A, Pochinco D, Gibson I, Ho J, Birk P, et al.
Am J Transplant
. 2016 Aug;
17(3):703-711.
PMID: 27539748
De novo donor-specific antibodies (dnDSAs) that develop after renal transplantation are independent predictors of allograft loss. However, it is unknown if dnDSA C1q status or titer at the time of...
2.
Naylor K, Lix L, Hans D, Garg A, Rush D, Hodsman A, et al.
Osteoporos Int
. 2015 Nov;
27(3):1115-1121.
PMID: 26608055
Summary: It is uncertain whether bone mineral density (BMD) can accurately predict fracture in kidney transplant recipients. Trabecular bone score (TBS) provides information independent of BMD. Kidney transplant recipients had...
3.
Wiebe C, Gibson I, Blydt-Hansen T, Pochinco D, Birk P, Ho J, et al.
Am J Transplant
. 2015 Jun;
15(11):2921-30.
PMID: 26096305
Understanding rates and determinants of clinical pathologic progression for recipients with de novo donor-specific antibody (dnDSA), especially subclinical dnDSA, may identify surrogate endpoints and inform clinical trial design. A consecutive...
4.
Wiebe C, Pochinco D, Blydt-Hansen T, Ho J, Birk P, Karpinski M, et al.
Am J Transplant
. 2013 Oct;
13(12):3114-22.
PMID: 24164958
De novo donor-specific antibody (dnDSA) develops in 15-25% of renal transplant recipients within 5 years of transplantation and is associated with 40% lower graft survival at 10 years. HLA epitope...
5.
Nickerson P, Rush D
Am J Transplant
. 2013 Aug;
13(9):2239-40.
PMID: 23911011
No abstract available.
6.
Nickerson P, Rush D
Am J Transplant
. 2013 Feb;
13(4):831-832.
PMID: 23406413
No abstract available.
7.
Wiebe C, Gibson I, Blydt-Hansen T, Karpinski M, Ho J, Storsley L, et al.
Am J Transplant
. 2012 Mar;
12(5):1157-67.
PMID: 22429309
The natural history for patients with de novo donor-specific antibodies (dnDSA) and the risk factors for its development have not been well defined. Furthermore, clinical and histologic correlation with serologic...
8.
Mengel M, Chapman J, Cosio F, Cavaille-Coll M, Haller H, Halloran P, et al.
Am J Transplant
. 2007 Jan;
7(3):512-7.
PMID: 17250556
A 1-day symposium on the application of protocol biopsies in renal transplantation was held in Boston, 21 July 2006. Representatives from centers with extensive experience in the use of protocol...
9.
Weber C, Rush D, Jeffery J, Cheang M, Karpinski M
Am J Transplant
. 2006 Jun;
6(8):1875-81.
PMID: 16771809
Aboriginal populations experience a very high rate of end-stage renal disease (ESRD); however, little is known about the outcomes of transplantation in this population. We performed a retrospective database review...
10.
Torng S, Rigatto C, Rush D, Nickerson P, Jeffery J
Transplantation
. 2001 Oct;
72(8):1453-6.
PMID: 11685120
Background: The purpose of this study was to examine the utility of the random urine protein to creatinine ratio (P/C) in evaluation and longitudinal management of proteinuria in adult renal...